Astrazeneca Ab

Karolina Lawitz

Peter Hansen

Asim Ray

Matti Juhani Lepistö

Hans Lönn

Antonios Nikitidis

Marianne Ivarsson

Martin Hemmerling

Karl Henrik Edman

Balint Gabos

Tomas Eriksson

Svetlana Ivanova

Grigorios Nikitidis

Lena Elisabeth Ripa

Peter Olof Sjö

Håkan Bladh

Peter Storm

Frank Burkamp

Antonio LLinas

Henrik Johansson

Matti Lepistö

This specification generally relates to 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds (including salts thereof). This specification also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including treatment methods and medicament preparations), and processes for making such a compound.

1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as SGRM modulators

The invention provides compounds of formula wherein R, R, R, R, R, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

The present invention provides compounds of formula (I) wherein n, p, R, R, X, X, X, X, X, R, R, R, Rand Rare as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.

Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy

The invention provides compounds of formula wherein R, R, R, R, R, R, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

The use of compounds of formula (I) wherein R, R, R, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is disclosed. Certain novel compounds of formula (I), together with processes for their preparation, compositions containing them and their use in therapy are also disclosed 

Use of and some novel imidazopyridines

The invention provides compounds of general formula (I), wherein R, X, Y, n, R, Z, Z, A, A, Q, R, R, R, R, R, R, t and Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy 

Amides, preparation and therapeutic use as modulators of CCR-receptor activity

Growing community of inventors

Lund, Sweden

Karolina Lawitz